论文部分内容阅读
1983年10月至1988年12月,作者对新诊断的70例Ⅰ期多发性骨髓瘤进行了研究,其中19例病人,由于高龄,严重的并发性疾病,不愿意参加以及肾功能衰竭或其他原因而除外,余51例病人随机分配到本病初期使用马法兰加强的松(MP)治疗组(n=25)与进展期MP治疗组(n=26),后者中的1例病人,因肾功能衰竭而从此组中除去。延期治疗组的病人从诊断到开始治疗中位时间为12个月。开始治疗组中有8例M蛋白增加;9例有症状性骨病,其中1例伴有M蛋白迅速增加,另1例M蛋白缓慢地增加,7例M蛋白稳定;5例有贫血,其中2例M蛋白增加,1例尿本周蛋白阳性,2例M蛋白稳定。疾病进展中2例合并脊柱骨折,并需要放疗。初期使用MP组中有2例发
From October 1983 to December 1988, the authors examined 70 newly diagnosed stage I multiple myeloma patients, of whom 19 were unwilling to participate due to advanced age, serious concomitant disease, and renal failure or other Except for the reason that 51 patients were randomly assigned to the MP prednisone group (n = 25) and the MP MP group (n = 26) in the early stage of the disease, and 1 patient in the latter group Renal failure was removed from this group. Patients in the deferred treatment group had a median time from diagnosis to initiation of treatment of 12 months. In the initial treatment group, there were 8 cases of M protein increased; 9 cases of symptomatic bone disease, one case accompanied by a rapid increase of M protein, another case of M protein increased slowly, 7 cases of M protein was stable; 5 cases of anemia, including 2 cases of M protein increased, 1 case of urine week protein positive, 2 cases of M protein stability. Two patients had spinal fractures in progress and needed radiotherapy. In the initial use of the MP group, 2 cases occurred